Ixekizumab

From Wikipedia, the free encyclopedia

Ixekizumab ^?
Monoclonal antibody
Type	Whole antibody
Source	Humanized
Target	IL-17a
Clinical data
Legal status	Investigational
Identifiers
CAS number	1143503-69-8^N
ATC code	None
Chemical data
Formula	C₆₄₉₂H₁₀₀₁₂N₁₇₂₈O₂₀₂₈S₄₆
Mol. mass	146.2 kDa
N (what is this?) (verify)

Ixekizumab is a humanized monoclonal antibody for the treatment of autoimmune diseases.^[1] More specifically, it is being tested for the use in psoriasis. A Phase II clinical trial including patients with moderate to severe psoriasis has been completed,^[2] and a Phase III open-label trial is under way as of November 2013.^[3]

Ixekizumab was developed by Eli Lilly and Co.

Mechanism of action

Ixekizumab binds to interleukin 17 and blocks its action. This mechanism is similar to that of another anti-psoriasis antibody, brodalumab, which however binds to the interleukin-17 receptor.^[2]

References

↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Ixekizumab". American Medical Association.
↑ 2.0 2.1 "Neue Antikörper in der Pipeline". Pharmazeutische Zeitung (in German) (12). 2012.
↑ ClinicalTrials.gov NCT01624233 A Study in Japanese Participants With Moderate-to-Severe Psoriasis

Monoclonal antibodies for the immune system

Immune system ("-l(i[m])-")

Human ("-limu-")	immunosuppression: Adalimumab Anifrolumab Atorolimumab Belimumab Brodalumab Carlumab Dupilumab Eldelumab Fresolimumab Golimumab Lerdelimumab Lirilumab Mavrilimumab Metelimumab Morolimumab Namilumab Oxelumab§ Placulumab Sarilumab Sifalimumab Tabalumab immune activation: Ipilimumab Tremelimumab Nivolumab Urelumab other: Bertilimumab Zanolimumab

Mouse ("-limo-")	Afelimomab Elsilimomab Faralimomab Gavilimomab Inolimomab Maslimomab Nerelimomab Odulimomab Telimomab aritox Vepalimomab Zolimomab aritox

Chimeric ("-lixi-")	Basiliximab Clenoliximab Galiximab Gomiliximab Infliximab Keliximab Lumiliximab Priliximab Teneliximab Vapaliximab

Humanized ("-lizu-")	immunosuppressive: Aselizumab Apolizumab Benralizumab^† Cedelizumab Certolizumab pegol Daclizumab Eculizumab Efalizumab Epratuzumab Erlizumab Etrolizumab Fontolizumab Itolizumab Lambrolizumab Lampalizumab Ligelizumab Mepolizumab Mogamulizumab Natalizumab Ocrelizumab Omalizumab Ozoralizumab Pascolizumab Pateclizumab Pexelizumab Pidilizumab PRO 140^† Reslizumab Rontalizumab Rovelizumab Ruplizumab Quilizumab Samalizumab Siplizumab Talizumab Teplizumab Tocilizumab Toralizumab Tregalizumab Vatelizumab Vedolizumab Visilizumab TGN1412^§ non-immunosuppressive: Ibalizumab^†

Chimeric + humanized ("-lixizu-")	Otelixizumab

Interleukin ("-k(i[n])-")

Human ("-kinu-")	Briakinumab Canakinumab Fezakinumab Guselkumab Secukinumab Sirukumab Tralokinumab Ustekinumab

Humanized ("-kizu-", "-kinzu-")	Anrukinzumab Clazakizumab Enokizumab Gevokizumab Ixekizumab Lebrikizumab Olokizumab Perakizumab Tildrakizumab

Inflammatory lesions ("-les-")

Mouse ("-leso-")	Besilesomab Fanolesomab^‡ Lemalesomab Sulesomab

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

M: LMC

cell/phys/auag/auab/comp, igrc

imdf/ipig/hyps/tumr

proc, drug (L3/4)

This article is issued from Wikipedia. The text is available under the Creative Commons Attribution/Share Alike; additional terms may apply for the media files.